A recent study suggests that individuals who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Research printed in a major medical journal shows that while overweight individuals often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"Users using these medications should be cognizant of the risk of quick rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to pre-treatment mass within about 18 months.
Analyzing Treatments
The analysis, which reviewed dozens of studies involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
The team note that people who lose weight through dieting usually see a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the injections accounts for the heightened weight return.
These medications mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement means hunger is unsuppressed, making overeating a significant risk."
A Chronic Issue?
Medical guidelines suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts say that, due to the likelihood of weight regain, the treatment is often ongoing.
This view is supported by pharmaceutical companies, who state that the results "emphasize the long-term nature of obesity," akin to managing conditions like hypertension.
User Experiences
People who have stopped the jabs report a powerful return of appetite.
"I experienced a switch flipping and I was suddenly ravenous," said a patient.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Growing Use
Survey data indicate that millions of people in the UK have tried these injections in the past year, with interest continuing to grow.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle support.
